Ann: Initial FDA and EMA Advice on Presendin Development, page-103

Definitely a good question to ask mate, although I'm in agreement that 51 is the real deal reputation wise.

I have a soft spot for 51 after overhearing their research report being discussed in a retail store to the equivalent of Harvey Norman, I asked the couple what ticker they were referring to after I heard Paradigm and it'll be "X amount by Xmas", and was sucked down the rabbit hole of their report and ended up getting a bag via PAR.

3 years later I find myself in another one of their holdings - although this time with a lot more education about biotechs and able to quantify with my own due diligence how good of an opportunity IXC really is.

Hoping the next 3-4 years are bountiful for us mate. GLTAH